Clinical trial NCT04726956: A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC
Official title: A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of Pancreatic Ductal Adenocarcinoma：A Multicenter Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Ductal Adenocarcinoma
Keywords: pancreatic ductal adenocarcinoma
CA199
AKR1B10
Lead sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2021-01-27
Enrollment: 258
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population included in the case group was patients with clinically and pathologically clear pancreatic ductal adenocarcinoma; and the population included in the benign group was patients with clinically and pathologically clear IPMN, mucinous cystadenoma, or pancreas cyst; and the population included in the control group was a healthy population without any benign or malignant diseases.

Brief summary: The purpose of this study is to clarify the diagnostic significance of AKR1B10 in patients with pancreatic ductal adenocarcinoma, and to combine with CA19-9 to improve the diagnosis rate of pancreatic ductal adenocarcinoma.


Eligibility criteria: General Inclusion Criteria

1. Age ≥ 18 years old;
2. Sign the informed consent form voluntarily;
3. Not a patient in the intensive care unit;

2. Patients with pancreatic ductal adenocarcinoma (PDAC group)

1. Two or more imaging studies (ultrasound, CT, MRI) found pancreatic tumors before operation, after surgical resection, intraoperative frozen pathology and postoperative pathology were clearly diagnosed as PDAC by 2 experienced pathologists, or diagnosed as pancreatic ductal adenocarcinoma by preoperative needle biopsy；
2. No other treatments such as radiotherapy or chemotherapy have been taken before the operation.

3. Benign disease group (Benign group)

1. Diagnosis of pancreatic intraductal papillary mucinous tumor (IPMN), mucinous cystadenoma or pancreas cyst based on clinical manifestations, clinical examinations, medical imagings (ultrasound/CT/MRI/ERCP), biopsy, and pathology
2. No relevant surgical treatment;

4. Healthy donors (Healthy group)

1. Healthy donors undergoing medical examinations at the above research centers;
2. Healthy donors of similar age without any benign or malignant diseases.

Exclusion Criteria:

1. PDAC group:

1. Patients who have undergone radiotherapy, chemotherapy and other tumor-related treatments before surgery;
2. Patients with non-primary pancreatic cancer;
3. Patients undergoing secondary operations;
4. Infected with HIV or AIDS related diseases;
5. Diagnosed as chronic or acute gastroenteritis;
6. Pregnant women;
7. Other situations that are not suitable for this research; 2. Benign group

(1) Patients who have undergone related surgical treatment in other hospitals; (2) Patients with a history of malignant tumors; 3. Healthy group:

1. Patients with a history of tumor;
2. Tumors found in medical examinations;
3. History of hepatitis B or C;
4. A history of acute or chronic gastroenteritis, cholecystitis, and cholangitis.

Primary outcomes:
measure: CA199 and AKR1B10 were detected in the sera of PDAC patients and Benign patients before surgery, as well as in the sera of healthy donors
timeFrame: 1 week
Secondary outcomes:
measure: CA125, CEA, and AFP were detected in the sera of PDAC and Benign patients before surgery, as well as in the sera of healthy donors
timeFrame: 1 week
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
state: Shanghai
city: Shanghai
country: China
facility: Changhai Hospital of Shanghai
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
Study officials:
References: